Published in BMC Pulm Med on May 09, 2009
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int (2010) 0.85
Renal disease in systemic sclerosis with normal serum creatinine. Clin Rheumatol (2010) 0.82
Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther (2015) 0.82
Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol (2015) 0.75
Relationship between Peripheral Arterial Stiffness and Estimated Pulmonary Pressure by Echocardiography in Systemic Sclerosis. Acta Cardiol Sin (2017) 0.75
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation (1984) 5.60
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Evaluation of clinical methods for rating dyspnea. Chest (1988) 4.12
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol (1985) 3.66
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Systemic inflammation in patients with COPD and pulmonary hypertension. Chest (2006) 3.30
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax (2005) 1.99
Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol (1989) 1.67
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res (2002) 1.52
Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation (2001) 1.34
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol (2001) 1.27
Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int (2000) 1.26
Pulmonary hypertension and inflammation. J Lab Clin Med (1998) 1.25
Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol (1998) 1.24
Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med (2000) 1.24
Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy (2003) 1.24
Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res (2006) 1.22
Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol (1998) 1.21
Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation (1989) 1.18
Systemic and localized scleroderma. Clin Dermatol (2006) 1.15
Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol (2006) 1.15
Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol (1985) (2002) 1.13
Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol (1998) 1.10
Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest (1996) 1.09
Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J (2007) 1.06
Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med (2002) 1.03
Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2003) 1.00
Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med (2000) 1.00
Left ventricular diastolic function in systemic sclerosis. J Rheumatol (2001) 0.80
Evaluation and management of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol (2003) 0.77
Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA (2013) 2.74
Bundle of measures for external cerebral ventricular drainage-associated ventriculitis. Crit Care Med (2014) 2.71
Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhal Toxicol (2013) 2.38
Differential cardiovascular responses during weaning failure: effects on tissue oxygenation and lactate. Intensive Care Med (2005) 2.12
Acute and short-term effects of secondhand smoke on lung function and cytokine production. Am J Respir Crit Care Med (2009) 2.10
Foxp3 expression in human cancer cells. J Transl Med (2008) 1.94
Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest (2007) 1.91
Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure. Int J Cardiol (2012) 1.68
The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD (2011) 1.61
Increased oxidative stress in exudative pleural effusions: a new marker for the differentiation between exudates and transudates? Chest (2005) 1.59
Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med (2011) 1.56
Cardiac and central vascular functional alterations in the acute phase of aneurysmal subarachnoid hemorrhage. Crit Care Med (2012) 1.54
Haemodialysis patients with sleep apnoea syndrome experience increased central adiposity and altered muscular composition and functionality. Nephrol Dial Transplant (2007) 1.46
The role of leptin in the respiratory system: an overview. Respir Res (2010) 1.30
Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res (2006) 1.22
Prevalence of chronic diseases and morbidity in primary health care in central Greece: an epidemiological study. BMC Health Serv Res (2010) 1.15
Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol (2010) 1.14
COPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry program. Prim Care Respir J (2010) 1.10
Underdiagnosis of respiratory diseases during an economic downturn and the need for spirometry as a screening test. J Bras Pneumol (2013) 1.09
The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord (2010) 1.07
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther (2007) 1.06
Helicobacter pylori infection and respiratory diseases: a review. World J Gastroenterol (2003) 1.06
Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest (2011) 1.04
Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med (2009) 1.03
Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir Med (2009) 1.03
Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol (2005) 1.03
Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Crit Care (2014) 1.03
Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med (2007) 1.01
VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer (2008) 0.99
The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med (2004) 0.99
Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem (2008) 0.98
New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients. Crit Care (2014) 0.98
Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med (2009) 0.97
Prevalence of sleep-related symptoms in a primary care population - their relation to asthma and COPD. Prim Care Respir J (2007) 0.96
Diabetes mellitus and lung function. Med Princ Pract (2003) 0.96
Linear-Endobronchial Ultrasound-guided Insertion of a Fiducial Marker: A New Tool for Tracking Central Lesions. J Bronchology Interv Pulmonol (2016) 0.96
Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif (2005) 0.95
Association of TLR4-T399I polymorphism with chronic obstructive pulmonary disease in smokers. Clin Dev Immunol (2010) 0.94
Depression and pulmonary function in outpatients with asthma. Respir Med (2004) 0.94
Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer (2004) 0.94
Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. Sleep Med (2008) 0.94
Exhaled NO and exhaled breath condensate pH in the evaluation of asthma control. Respir Med (2010) 0.94
Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.94
Global assessment of the COPD patient: time to look beyond FEV1? Respir Med (2009) 0.93
Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem (2009) 0.92
Noninvasive ventilation in chronic respiratory failure: effects on quality of life. Respiration (2010) 0.92
Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J (2013) 0.91
Associations between BODE index and systemic inflammatory biomarkers in COPD. COPD (2011) 0.91
The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma. Cytokine (2013) 0.90
The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J (2012) 0.90
Unilateral pulmonary edema due to pulmonary venous obstruction from fibrosing mediastinitis. Int J Cardiol (2006) 0.89
Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord (2007) 0.89
Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther (2011) 0.89
Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2006) 0.88
Respiratory diseases and Helicobacter pylori infection: is there a link? Respiration (2006) 0.88
Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis. Respir Med (2005) 0.88
Vascular endothelial growth factor levels in pleural fluid and serum of patients with tuberculous pleural effusions. Chest (2005) 0.88
Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther (2007) 0.88
Oxidative stress in patients with obstructive sleep apnea syndrome. Sleep Breath (2012) 0.88
Oxidative stress in patients with COPD. Curr Drug Targets (2011) 0.88
A brief exposure to moderate passive smoke increases metabolism and thyroid hormone secretion. J Clin Endocrinol Metab (2006) 0.88
Effects of hypoxia on diaphragmatic fatigue in highly trained athletes. J Physiol (2007) 0.88
Prognostic value of C-reactive protein in parapneumonic effusions. Respirology (2012) 0.86
Atypical presentation of varicella-zoster virus encephalitis in an immunocompetent adult. Heart Lung (2008) 0.86
Vibration response imaging: evaluation of rater agreement in healthy subjects and subjects with pneumonia. BMC Med Imaging (2010) 0.86
Venous oxygen saturation and lactate gradient from superior vena cava to pulmonary artery in patients with septic shock. Shock (2009) 0.86
The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. Respir Med (2011) 0.85
Clinical significance of serum adipokines levels in lung cancer. Med Oncol (2013) 0.85
Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. Respir Res (2011) 0.85
Alterations of deadenylase expression in acute leukemias: evidence for poly(a)-specific ribonuclease as a potential biomarker. Acta Haematol (2012) 0.85